** Ebiogen Obtains Export Manufacturing Certification for Urine-Based 20-Drug Detection Kit **
2026-05-20
본문
Ebiogen Inc. has obtained export manufacturing certification for BAROS-N20C-UriA-E, a urine-based 20-drug detection kit designed to qualitatively detect drugs and related metabolites in human urine samples.
With this certification, Ebiogen has officially secured the basis for manufacturing and exporting the product to overseas markets, further strengthening its capability to supply rapid drug screening solutions internationally. The kit is based on immunochromatographic assay technology and is intended to help screen for the presence of 20 drug categories and related metabolites, including methamphetamine, ketamine, zolpidem, cocaine, morphine, amphetamine, benzodiazepines, and others.
Ebiogen has continuously developed point-of-care and rapid test products across various fields, including drug detection, environmental hygiene testing, and allergen detection, based on its accumulated expertise in lateral flow assay technology and in-vitro diagnostic product development. The acquisition of this export manufacturing certification marks an important milestone in expanding the company’s global business opportunities and demonstrating its product development and quality management capabilities.
Ebiogen will continue its efforts to develop reliable, Korea-manufactured rapid test and in-vitro diagnostic products, while expanding cooperation with global partners to contribute to public health, safety management, and on-site screening needs worldwide.
